MZT2B promotes malignant phenotypes in NSCLC cells by enhancing mitochondrial function and COX5B expression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality, with a need for novel therapeutic targets.
• Mitotic spindle organizing protein 2B (MZT2B) has emerged as a potential oncogenic driver in various cancers.

Purpose of the Study:

• To investigate the role of MZT2B as a therapeutic target in NSCLC.
• To elucidate the molecular mechanisms underlying MZT2B's function in NSCLC progression.

Main Methods:

• TCGA and single-cell RNA sequencing analyses for MZT2B expression.
• In vitro studies involving MZT2B knockdown/knockout in NSCLC cell lines.
• Mitochondrial function assays and Western blotting.
• In vivo xenograft models in mice.

Main Results:

• MZT2B is significantly upregulated in NSCLC tissues and correlates with poor prognosis.
• MZT2B silencing/knockout inhibits NSCLC cell viability, proliferation, migration, and invasion, inducing cell cycle arrest and apoptosis.
• MZT2B is critical for mitochondrial respiration, ATP production, and redox homeostasis.
• MZT2B promotes NSCLC progression partly via regulating cytochrome c oxidase subunit 5B (COX5B) expression.
• MZT2B knockdown impairs tumor growth in vivo.

Conclusions:

• MZT2B is a critical oncogenic driver and potential therapeutic vulnerability in NSCLC.
• MZT2B regulates NSCLC progression by maintaining mitochondrial function and influencing COX5B expression.
• Targeting MZT2B may represent a promising therapeutic strategy for NSCLC.